AURORA CANNABIS INC

Aurora Cannabis announced its full-year and fourth-quarter fiscal 2026 results, highlighting record annual global medical cannabis net revenue of $288.6 million (up 18% YoY) and record annual Adjusted EBITDA of $53.8 million (up 32% YoY). The company also completed the accretive acquisition of Safari Flower Company, adding critical EU-GMP certified capacity. While Q4 revenue saw a 10% increase to $84.8 million, driven by medical cannabis growth, Adjusted EBITDA for the quarter decreased to $9.2 million from $14.1 million in the prior year. Aurora maintains a strong balance sheet with significant cash reserves and no debt.

Aurora Cannabis Inc. announced it will host an investor conference call on Thursday, June 11, 2026, at 8:00 a.m. Eastern Time. The call is scheduled to discuss the company's financial results for the fourth quarter and fiscal year 2026. The results will be released before the market opens on the same day.

Aurora Cannabis Inc. announced the details for its upcoming Annual General Meeting (AGM). The meeting is scheduled for August 7, 2026, and will be held virtually. The record date for both notice of meeting and voting purposes has been set for June 15, 2026.

Aurora Cannabis Inc. announced it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars, Farm Gas™ and Driftwood Diesel™. This certification provides Aurora with exclusive rights to grow, propagate, and sell finished products from these varieties, strengthening its leadership in cannabis science and enhancing its global competitive position. These cultivars are core medical cannabis products available in multiple international markets.

AURORA CANNABIS INC filed a Form 6-K with the SEC on April 28, 2026. This filing included the submission of a news release dated April 28, 2026. The specific details and content of the news release were not provided in the extracted text.